Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | DNM1 | Q05193 | 8/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10383392 | 1.00 | ALDH1A1 (0.64) | ALDH1A1TDP1LMNAOPRM1DNM1 | |
| SCHEMBL11042224 | 1.00 | ALDH1A1 (0.64) | ALDH1A1TDP1LMNAOPRM1DNM1 | |
| SCHEMBL20495959 | 1.00 | ALDH1A1 (0.64) | ALDH1A1TDP1LMNAOPRM1DNM1 | |
| SCHEMBL14436836 | 1.00 | ALDH1A1 (0.64) | ALDH1A1TDP1LMNAOPRM1DNM1 | |
| SCHEMBL24684882 | 1.00 | ALDH1A1 (0.64) | ALDH1A1TDP1LMNAOPRM1DNM1 | |
| SCHEMBL22658086 | 1.00 | ALDH1A1 (0.64) | ALDH1A1TDP1LMNAOPRM1DNM1 | |
| SCHEMBL24200454 | 1.00 | ALDH1A1 (0.64) | ALDH1A1TDP1LMNAOPRM1DNM1 | |
| SCHEMBL22342116 | 1.00 | ALDH1A1 (0.64) | ALDH1A1TDP1LMNAOPRM1DNM1 | |
| SCHEMBL20495968 | 1.00 | ALDH1A1 (0.64) | ALDH1A1TDP1LMNAOPRM1DNM1 | |
| SCHEMBL8619929 | 1.00 | ALDH1A1 (0.64) | ALDH1A1TDP1LMNAOPRM1DNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200388934-A1 | TFT SUBSTRATE, METHOD FOR MANUFACTURING TFT SUBSTRATE, AND SCANNED ANTENNA | SHARP KABUSHIKI KAISHA (JP) | 2020-12-10 | — | — | US | disclosed |
| US-20160318847-A1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | ACADIA PHARMACEUTICALS INC. | 2016-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318847-A1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | SLC6A4, HTR4, GPR34 | ALDH1A1 3075/4885TDP1 1109/4885LMNA 869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.